Company profile: ADMA Biologics
1.1 - Company Overview
Company description
- Provider of plasma-based biologics, including ASCENIV IVIG for primary immunodeficiency disease (PIDD) and other immune-compromised conditions; BIVIGAM IVIG for primary humoral immunodeficiency (PI); Nabi-HB hyperimmune globulin to prevent hepatitis B infection following exposure; and ADMA BioCenters, a network of plasma collection centers supplying high-quality plasma for immunoglobulin manufacturing.
Products and services
- ASCENIV: Plasma-derived IVIG engineered for intravenous administration to treat primary immunodeficiency disease (PIDD) and other immune-compromised conditions, delivering broad passive immunoglobulin support
- BIVIGAM: Intravenous immunoglobulin (IVIG) formulated for systemic infusion to treat primary humoral immunodeficiency (PI), furnishing exogenous antibodies to bolster deficient immune responses
- Nabi-HB: Hyperimmune globulin administered after exposure to the hepatitis B virus to prevent hepatitis B infection, conferring immediate passive immunity.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ADMA Biologics
Amagma Therapeutics
HQ: United States
Website
- Description: Provider of discovery and development of antibody therapeutics targeting inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amagma Therapeutics company profile →
Sitryx
HQ: United Kingdom
Website
- Description: Provider of cell metabolism–targeted, first-in-class, disease-modifying therapeutics in immuno-oncology and immuno-inflammation. Pipeline includes SYX-5219 for atopic dermatitis; SIT-052, an inhaled GLS1 inhibitor for pulmonary fibrosis and COPD that selectively breaks down senescent cells; SIT-033, a SIK2 inhibitor for ulcerative colitis; and SYX-1042 and SIT-047 for autoimmune indications (with Eli Lilly).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sitryx company profile →
CalciMedica
HQ: United States
Website
- Description: Provider of CRAC channel inhibitor therapies for acute and chronic inflammatory diseases, including Auxora, an IV CRAC inhibitor in development for acute pancreatitis, asparaginase-induced pancreatic toxicity, acute kidney injury, and ARDS, and oral CRAC inhibitors for conditions such as chronic pancreatitis and rheumatoid arthritis. Conducts clinical trials including CARPO, CRSPA, KOURAGE, and CARDEA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CalciMedica company profile →
BioAtla
HQ: United States
Website
- Description: Provider of conditionally active biologics (CABs) for cancer-targeted therapeutics activated under specific physiological conditions; the CIAO! platform for antibody optimization; CAB-ADCs, CAB-CAR-T, and CAB-Bispecifics to improve safety and efficacy; and Mecbotamab Vedotin, a CAB-AXL-ADC for AXL-expressing tumors evaluated in sarcoma and NSCLC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioAtla company profile →
Rigel Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule drugs for autoimmune, cancer and metabolic diseases, offering REZLIDHIA (olutasidenib) for relapsed/refractory AML with IDH1 mutation and TAVALISSE (fostamatinib) for adult chronic ITP; pipeline includes R289 for LR-MDS, milademetan (MDM2) for liposarcoma with Daiichi Sankyo, bemcentinib (AXL) for NSCLC with BerGenBio, and R552 (RIPK1) for rheumatoid arthritis with Eli Lilly.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rigel Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ADMA Biologics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ADMA Biologics
2.2 - Growth funds investing in similar companies to ADMA Biologics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ADMA Biologics
4.2 - Public trading comparable groups for ADMA Biologics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →